ROARABLE
FREE $100K
My Trading Account →
▾
Trading Account Active
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / QURE / news
STOK (46) NUVB (19) KLRA (45) ANIP (63) ⌘ Pro Terminal →

Why QURE Stock dropped -7.49% Today — RQD Quant Desk Flash

$22.97 -7.49% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $22.62

uniQure N.V. (QURE) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $1.72B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on QURE Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is QURE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, uniQure N.V. (NASDAQ: QURE) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $22.97 (-7.49% 1D, market cap $1.72B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, QURE ranks #500 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does QURE compare to STOK and NUVB in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), QURE carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, STOK (Stoke Therapeutics Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC -6.1%, cap $1.70B) and NUVB (Nuvation Bio Inc. (Class A)) posts a E grade (19/100 RQD, P/E N/A, ROIC -35.0%, cap $1.67B). Among the 5-stock peer group, ANIP leads on earnings multiple (21.5x) while ANIP leads on capital efficiency (16.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for QURE?
▼

Per QURE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001590560), uniQure N.V. generated $519.0M in revenue (+0.6% YoY), -$199.0M in net income, and -$178.4M in free cash flow against $824.9M in total assets and $49.7M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $22.62 (-1.54%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.8% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510038
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D+
Cash (6)Whales (5)SEC (13)Macro (9)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-9% Base Target
$54 Bull$21 Base$16 Bear
📬 FREE QURE RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for QURE)Realized 20D OHLCV Swing Band: ±11.2%
Deterministic 5-Pillar Attribution (38/100 Composite)
🔍 WHY QURE SCORES 38/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (34% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Macro Regime Fit+9/20 pts (24% of score)

FRED Regime × Technicals: 33% of 52W Range • RSI-14 at 42.9 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
30
Grade E$21.28+6.8% Next Q
Q2 (-2Q)
33
Grade E$22.72+6.9% Next Q
Q3 (-1Q)
35
Grade E$24.28-5.4% Next Q
Current
38
Grade D-$22.97-7.8% Hist 90D α
Trajectory: E (30) → D- (38)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a QURE Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While QURE currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($33.64) and Max Pain ($24.12) forces dealer call-delta covering toward $54.31.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $QURE• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “QURE Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 38%NO 62%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why QURE Stock dropped -7.49% Today — RQD Quant Desk Flash

uniQure N.V. (QURE) dropped -7.49% to $22.97, trading at 33% of its 52-week range ($8.73 – $51.72). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 33% of its 52-week range ($8.73 – $51.72) with RSI-14 at 42.9 (NEUTRAL RANGE).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±11.2% around $22.97 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live QURE Headlines & Catalysts
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring QURE)

  • ✓Walkthrough of QURE's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
QURE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +11.07%📐 HORIZONTAL RANGE
2026-11-03O $25.30H $25.30L $22.97C $22.97VOL 1.90M
RES: $53.18SUP: $19.81SMA50: $33.64SMA200: $29.68
$54.18$44.00$33.82$23.65$13.47RES $53.18SUP $19.81$22.972026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

QURE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 QURE Butterfly Map → + Track QURE →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +0.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on QURE today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for QURE. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for QURE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (QURE)

Health Care Rank #500 of 1015 ⚔️ STOK vs QURE Full Matrix →

1. Head-to-Head Health Care Peer Comparison (QURE vs. STOK, NUVB, KLRA, ANIP)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, uniQure N.V. (QURE) ranks #500 by composite RQD confidence (38/100, grade D-) and #277 by equity capitalization ($1.72B). Within this direct 5-issuer industry benchmark cohort, ANIP leads on earnings valuation at 21.5x trailing P/E, while ANIP leads on capital efficiency and profitability with 16.0% ROIC and — gross margin. ANIP currently holds the highest overall quantitative score in the immediate peer group at 63/100 (C) compared with QURE at 38/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
QURE ACTIVE
uniQure N.V.
D- 38/100 — — -35.0% -7.49% $1.72B Benchmark Subject
STOK
Stoke Therapeutics Inc.
D 46/100 — — -6.1% +0.72% $1.70B /stok-vs-qure →
NUVB
Nuvation Bio Inc. (Class A)
E 19/100 — — -35.0% -3.57% $1.67B /nuvb-vs-qure →
KLRA
Kailera Therapeutics Inc.
D 45/100 — — — -5.52% $1.67B /klra-vs-qure →
ANIP
ANI Pharmaceuticals Inc.
C 63/100 21.5x — 16.0% -1.85% $1.65B /anip-vs-qure →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001590560 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), uniQure N.V. (QURE) reported GAAP revenue of $519.0M (+0.6% vs. FY2024 revenue of $516.0M , and -34.5% cumulative change since FY2023) , GAAP net income of -$199.0M, operating cash flow of -$178.0M, and free cash flow of -$178.4M (+4.1% YoY). On the balance sheet, QURE closed FY2025 with $824.9M in total assets against $49.7M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $519.0M -$199.0M -$178.0M -$178.4M $824.9M $49.7M
FY2024 (FY) 2024-12-31 $516.0M -$239.6M -$182.7M -$186.1M $556.5M $51.3M
FY2023 (FY) 2023-12-31 $792.0M -$308.5M -$145.9M -$145.9M — —

3. QURE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is QURE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, uniQure N.V. (NASDAQ: QURE) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $22.97 (-7.49% 1D, market cap $1.72B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, QURE ranks #500 in composite RQD confidence.

How does QURE compare to STOK and NUVB in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), QURE carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, STOK (Stoke Therapeutics Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC -6.1%, cap $1.70B) and NUVB (Nuvation Bio Inc. (Class A)) posts a E grade (19/100 RQD, P/E N/A, ROIC -35.0%, cap $1.67B). Among the 5-stock peer group, ANIP leads on earnings multiple (21.5x) while ANIP leads on capital efficiency (16.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for QURE?

Per QURE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001590560), uniQure N.V. generated $519.0M in revenue (+0.6% YoY), -$199.0M in net income, and -$178.4M in free cash flow against $824.9M in total assets and $49.7M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is QURE trading relative to its 50-day, 200-day, and 52-week technical levels?

QURE last traded at $22.97 (-7.49% on volume of 6,441,708 shares), positioning the stock -31.72% below its 50-day simple moving average ($33.64) and -22.61% below its 200-day simple moving average ($29.68). Across its 52-week range of $8.73 to $51.72, QURE sits at the 33.1% percentile with a 14-day RSI of 42.9 (NEUTRAL RANGE) and an implied next-earnings move of ±11.2% ($20.40 to $25.54).

Direct Sub-Reports: QURE RQD Cockpit QURE 12M Forecast QURE Earnings & Move QURE Dividends & DRIP QURE Insiders & 13F QURE Whale Options QURE Profit Sankey QURE News & Why
ROARABLE RATING BRIEF • RQD 38/100 (D-) ✓ SEC XBRL & RQD VERIFIED

QURE — uniQure N.V.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

uniQure N.V. (QURE) earns a live Roarable RQD composite score of 38/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $22.97 (-7.49% 1D, market capitalization $1.72B).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -10.17%.
  • Whale 13F & Options Flow (5/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 4/9, and Debt/Equity of 0.25x.

2. Business Model, Unit Margins & SEC Financial Trajectory

UniQure N.V. (QURE) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. Revenue is reported as — across the available periods. — for further business detail.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), uniQure N.V. (QURE) reported $519.0M in annual revenue (up from $516.0M in FY2024, +0.6% YoY) and -$199.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($792.0M revenue, -$308.5M net income) through FY2025, QURE scaled operating cash flow to -$178.0M and free cash flow to -$178.4M, backed by $824.9M in total assets against $49.7M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 38/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -10.17% and institutional whale pillar of 5/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $8.73 – $51.72 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), QURE carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can QURE sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $519.0M and free cash flow of -$178.4M, how will capital allocation balance growth reinvestment against $49.7M in total debt?
  • Key Question #3: How sensitive is QURE's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

QURE Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for uniQure N.V. (QURE) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to QURE Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

QURE Bull vs. Bear Conversation Board — What's Your Call at $22.97?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON QURE 🐻 33% BEARISH CONVICTION
1. Pick Your Side on QURE:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH 🎯 Target: $28.80 (+16.0%)
📌 Pinned Debate

Forensic balance-sheet pillar scores 13/20 with Debt/Equity of 0.25 and Altman Z of 2.5, the strongest pillar in the rating.

Picked up a starter position in QURE in my $100K Virtual Cash book at $24.83. Forensic balance-sheet pillar scores 13/20 with Debt/Equity of 0.25 and Altman Z of 2.5, the strongest pillar in the rating.. Trading inside a $8.73–$51.72 52-week range with -10.17% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.

EarningsSniper 🐂 BULL

@RiskArb_Desk Shorting a 5/20 institutional whale-flow stock at $24.83 is dangerous when funds are rotating into Health Care.

RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH 🎯 Target: $18.62 (-25.0%)
Spot @ $24.83

Negative ROIC of -35% and FCF yield of -10.17% with zero reported revenue leave no cash-generation support for the valuation.

Here is the bear case nobody on the bull side wants to address on QURE: Negative ROIC of -35% and FCF yield of -10.17% with zero reported revenue leave no cash-generation support for the valuation.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.

LIVE TAPE